This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Prescription rates for urinary tract infections (UTI) as a marker for bladder and renal cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Prescription rates for urinary tract infections (UTI) as a marker for bladder and renal cancer

  • study found evidence for an increase in the rate of prescriptions for UTIs from baseline 9 months before diagnosis of renal and bladder cancer
    • an earlier infection point for UTI antibiotic prescriptions was noted in women than in men (11 vs 7 months) prior to bladder cancer diagnosis
      • inflection points for an increase in UTI prescriptions were identified 9 months pre-diagnosis for renal (CI:5.3-12.7) and bladder (CI:7.4-
        10.6) cancers
      • for bladder cancer, the change in UTI antibiotic prescription rates occurred four months earlier in women (11 months, CI:9.7-12.3) than men (7 months, CI:5.4-8.6)
    • the study authors concluded:
      • prescription rates for UTIs increased 9 months before bladder and renal cancer diagnosis, indicating that there is potential to expedite diagnosis of these cancers in patients presenting with features of UTI

Reference:

  • Funston G et al. Pre-diagnostic prescription patterns in bladder and renal cancer: a longitudinal linked data study. British Journal of General Practice 1 September 2023; BJGP.2023.0122. DOI: 10.3399/BJGP.2023.0122

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.